However, the discovery of pathogenic autoantibodies to aquaporin-4 (AQP4) in patients with NMO, which are absent in MS, led to the recognition of NMO as a disease entity in its own right [2–4] and generated strong and persisting interest in the syndrome. This evidence concerns the gene AQP4 and myeloid sarcoma.